Literature DB >> 7717402

Cytogenetic and molecular studies of Down syndrome individuals with leukemia.

J J Shen1, B J Williams, A Zipursky, J Doyle, S L Sherman, P A Jacobs, A L Shugar, S W Soukup, T J Hassold.   

Abstract

There is an increased risk of leukemia in Down syndrome (DS) patients, with estimates ranging from 14 to 30 times the incidence rate observed for chromosomally normal children. Furthermore, one type of leukemia, called "transient leukemia" (TL), occurs almost exclusively in DS infants. The basis of the association between DS and leukemia is unknown, but we and others have hypothesized that it may be influenced by the mechanism of origin of the extra chromosome. Therefore, we initiated a cytogenetic and molecular study of nondisjunction in leukemia DS individuals. To date, we have obtained blood and/or tissue samples from 55 individuals consisting of 17 cases with TL, 7 cases of acute nonlymphocytic leukemia subtype M7 (ANLL-M7, or acute megakaryoblastic leukemia, postulated to be related to TL), and 31 cases of other forms of leukemia. Analysis of these cases suggests differences between DS children with TL and those with other types of leukemia or DS individuals with no history of leukemia. Specifically, the TL and ANLL-M7 cases have a highly significant increase in the frequency of "atypical" constitutional karyotypes (i.e., mosaic trisomies, rings, and/or isochromosomes) and are almost always male. Additionally, genetic mapping studies suggest an increase in the frequency of disomic homozygosity, especially in proximal 21q, in DS individuals with TL and ANLL-M7.

Entities:  

Mesh:

Year:  1995        PMID: 7717402      PMCID: PMC1801215     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  17 in total

1.  Characterization and molecular analysis of nondisjunction in 18 cases of trisomy 21 and leukemia.

Authors:  B J Lorber; S B Freeman; T Hassold; A H Ragab; R A Vega; A E Cockwell; P A Jacobs; M Radford; J Doyle; I D Dubé
Journal:  Genes Chromosomes Cancer       Date:  1992-04       Impact factor: 5.006

2.  Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome.

Authors:  K Abe; T Kajii; N Niikawa
Journal:  Hum Genet       Date:  1989-07       Impact factor: 4.132

3.  Whole genome amplification from a single cell: implications for genetic analysis.

Authors:  L Zhang; X Cui; K Schmitt; R Hubert; W Navidi; N Arnheim
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

4.  Trisomy 21: association between reduced recombination and nondisjunction.

Authors:  S L Sherman; N Takaesu; S B Freeman; M Grantham; C Phillips; R D Blackston; P A Jacobs; A E Cockwell; V Freeman; I Uchida
Journal:  Am J Hum Genet       Date:  1991-09       Impact factor: 11.025

5.  'Touchdown' PCR to circumvent spurious priming during gene amplification.

Authors:  R H Don; P T Cox; B J Wainwright; K Baker; J S Mattick
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

6.  Methods for genetic linkage analysis using trisomies.

Authors:  E Feingold; N E Lamb; S L Sherman
Journal:  Am J Hum Genet       Date:  1995-02       Impact factor: 11.025

7.  Leukaemia and transient leukaemia in Down syndrome.

Authors:  L Iselius; P Jacobs; N Morton
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

Review 8.  Leukemia in Down syndrome: a review.

Authors:  A Zipursky; A Poon; J Doyle
Journal:  Pediatr Hematol Oncol       Date:  1992 Apr-Jun       Impact factor: 1.969

9.  Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis.

Authors:  J R Korenberg; C Bradley; C M Disteche
Journal:  Am J Hum Genet       Date:  1992-02       Impact factor: 11.025

Review 10.  Megakaryoblastic leukemia and Down's syndrome: a review.

Authors:  A Zipursky; M Peeters; A Poon
Journal:  Pediatr Hematol Oncol       Date:  1987       Impact factor: 1.969

View more
  9 in total

1.  Is disomic homozygosity at the APECED locus the cause of increased autoimmunity in Down's syndrome?

Authors:  J P Shield; E J Wadsworth; T J Hassold; L A Judis; P A Jacobs
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

2.  Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome.

Authors:  M Richards; J Welch; A Watmore; D Readett; A J Vora
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

3.  Studies of non-disjunction in trisomies 2, 7, 15, and 22: does the parental origin of trisomy influence placental morphology?

Authors:  M V Zaragoza; E Millie; R W Redline; T J Hassold
Journal:  J Med Genet       Date:  1998-11       Impact factor: 6.318

4.  Statistical models for trisomic phenotypes.

Authors:  N E Lamb; E Feingold; S L Sherman
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

Review 5.  Myeloid leukemia in Down syndrome.

Authors:  Irum Khan; Sébastien Malinge; John Crispino
Journal:  Crit Rev Oncog       Date:  2011

6.  Bacterial contig map of the 21q11 region associated with Alzheimer's disease and abnormal myelopoiesis in Down syndrome.

Authors:  J Groet; J H Ives; A P South; P R Baptista; T A Jones; M L Yaspo; H Lehrach; M C Potier; C Van Broeckhoven; D Nizetić
Journal:  Genome Res       Date:  1998-04       Impact factor: 9.043

7.  Isolation of a cosmid clone corresponding to an inv(21) breakpoint of a patient with transient abnormal myelopoiesis.

Authors:  T Ohta; M Nakano; T Tsujita; K Abe; K Osoegawa; T Yamagata; K Yoshiura; Y Jinno; E Soeda; Y Nakamura; N Niikawa
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

8.  CD19-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired karyotypic abnormality.

Authors:  Hua-feng Wang; Yi-zhi Cheng; Huan-ping Wang; Zhi-mei Chen; Ji-yu Lou; Jie Jin
Journal:  J Zhejiang Univ Sci B       Date:  2009-11       Impact factor: 3.066

9.  Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.

Authors:  S De Vita; C Canzonetta; C Mulligan; F Delom; J Groet; C Baldo; L Vanes; F Dagna-Bricarelli; A Hoischen; J Veltman; E M C Fisher; V L J Tybulewicz; D Nizetic
Journal:  Oncogene       Date:  2010-08-09       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.